Brian Singerman

Brian Singerman is a partner at Founders Fund, a San Francisco-based venture capital firm with over $11 billion under management.[1]

Brian Singerman
Alma materStanford University
OccupationPartner at Founders Fund
Known forFounder of iGoogle

Singerman graduated from Stanford University in 1999 with a B.S. in Computer Science.[2] Following Stanford, Singerman joined the virtual-world online start-up, There, as a software engineer. In 2004, Singerman joined Google.[3] He spent the next four years there as an engineer and executive and founded the personal web portal, iGoogle.[4]

While at Google, Singerman started his career as an investor, launching a $1 million fund called XGYC Fund, short for "ex-Google, Y Combinator.[5] In 2008, Singerman joined Founders Fund where he serves as a partner along with Peter Thiel and Ken Howery. Among other industries, he focuses on healthcare, biotech, wearable computing and robotics. Singerman is a board director for Affirm, AltSchool, Cloud9, Emerald Therapeutics, The Long-Term Stock Exchange, Oscar Health and Postmates, and a board observer for Airbnb, Forward and Wish.

In April 2016, Singerman's largest investment to date, Stemcentrx, was acquired by pharmaceutical company AbbVie in a transaction valuing the company at up to $10.2 billion. The acquisition was the largest portfolio exit in the history of Founders Fund.[6] Stemcentrx was shuttered in 2019 when its cancer drug, Rova-T, failed to outperform placebo in a Phase 3 clinical trial.[7]

References
  1. "A look inside Founders Fund, as it closes on $5 billion across two new funds". TechCrunch. Retrieved 2 August 2023.
  2. Brian Singerman bio at Founders Fund
  3. "Move Over, Peter Thiel -- How Brian Singerman Became Founders Fund's Top VC". Forbes. Retrieved 2 August 2023.
  4. Markowitz, Eric (April 25, 2012). "Founders 50: Is This the Most Exclusive Tech Conference Ever". Inc.
  5. "Move Over, Peter Thiel -- How Brian Singerman Became Founders Fund's Top VC". Forbes. Retrieved 2 August 2023.
  6. "Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund". Bloomberg.com. 2016-04-28. Retrieved 2021-01-08.
  7. "Xconomy: $5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop". Xconomy. 2019-08-29. Retrieved 2021-01-08.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.